Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Brentuximab Vedotin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EC Approves Adcetris for Treating Adult Hodgkin Lymphoma
    EC Approves Adcetris for Treating Adult Hodgkin Lymphoma

    03 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250603992751/en/European-Commission-Approves-ADCETRIS-brentuximab-vedotin-for-the-Treatment-of-Adult-Patients-with-Newly-Diagnosed-Stage-IIbIIIIV-Hodgkin-Lymphoma-in-Combination-with-ECADD

    BUSINESSWIRE
    03 Jun 2025
    Share Share
    Pfizer reports positive results from Echelon-3 study
    Pfizer reports positive results from Echelon-3 study

    17 Jun 2024

    // INDIANPHARMAPOST

    https://www.indianpharmapost.com/diagnostic-center/pfizer-reports-positive-results-from-echelon-3-study-15773

    INDIANPHARMAPOST
    17 Jun 2024
    Share Share
    Takeda and Pfizer announce results from Positive Phase 3
    Takeda and Pfizer announce results from Positive Phase 3

    03 Jun 2024

    // PRESS RELEASE

    https://www.takeda.com/newsroom/newsreleases/2024/four-year-results-from-positive-phase-3-hd21-trial/

    PRESS RELEASE
    03 Jun 2024
    Share Share
    Frontline ADCETRIS Combo Shows 4-Year Survival Benefit In Hodgkin Lymphoma
    Frontline ADCETRIS Combo Shows 4-Year Survival Benefit In Hodgkin Lymphoma

    01 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240601381068/en

    BUSINESSWIRE
    01 Jun 2024
    Share Share
    ADCETRIS Regimen Improves OS In Relapsed/Refractory DLBCL
    ADCETRIS Regimen Improves OS In Relapsed/Refractory DLBCL

    01 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240601866996/en

    BUSINESSWIRE
    01 Jun 2024
    Share Share
    Seagen’s former commercial chief joins the board at healthcare agency
    Seagen’s former commercial chief joins the board at healthcare agency

    22 Mar 2024

    // Beth Snyder Bulik ENDPTS

    https://endpts.com/seagens-former-commercial-chief-joins-the-board-at-healthcare-agency-minds-assembly/

    Beth Snyder Bulik ENDPTS
    22 Mar 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.